A Pro-Somathropic and Thyrogenic Formulation with GH and Free T3 Elevative Features for the Treatment of Growth Defects & Dwarfism
Principal Investigator(s): View help for Principal Investigator(s) Erdal Can Alkoclar, Mas Pharmaceuticals; Metehan Yesil, Mas Pharmaceuticals
Version: View help for Version V1
| Name | File Type | Size | Last Modified |
|---|---|---|---|
|
|
application/pdf | 2.2 MB | 04/26/2020 06:57:AM |
|
|
application/vnd.openxmlformats-officedocument.wordprocessingml.document | 24.3 KB | 04/22/2020 09:01:PM |
Project Citation:
Alkoclar, Erdal Can, and Yesil, Metehan . A Pro-Somathropic and Thyrogenic Formulation with GH and Free T3 Elevative Features for the Treatment of Growth Defects & Dwarfism. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2020-04-26. https://doi.org/10.3886/E119143V1
Project Description
Summary:
View help for Summary
A SOMATOTROPIC AND PRO-THYROGENIC COMPOSITION FORMED
FOR TREATING GROWTH/DEVELOPMENT/DWARFISM SYNDROMES
Technical Field
The invention relates to a somatotropic and pro-thyrogenic composition formed for treating growth/development/dwarfism syndromes.
State of the Art
Dwarfism is a condition of an individual who is smaller than the normal and who lacks the ability of normal development. Dwarfism occurs in the animals and also in the plants. It is not possible to make a certain classification as to what height would cause a human to be called a dwarf. The height that leads an adult human to be considered as a dwarf generally varies between one and one and a half meter. Normal persons may have dwarf children and the dwarf persons may have normal children. The causes of dwarfism in the human may be examined in two groups, namely the congenital dwarfism and the dwarfism that occurs later in life due to some diseases. Dwarfism resulting from disease: The dwarfism may result from chronic kidney disease, cystic fibrosis and celiac disease where the nutrient absorption is impaired, the heart and lung diseases where there is low oxygen level in the blood, and the malnutrition during the early years of life. The treatment of these diseases generally provides a treatment for the dwarfism also. The treatable type of dwarfism known as the pituitary dwarfism is the type in which the medicine has the biggest interest. This generally results from the inability of the pituitary gland to secrete sufficient growth hormone. Although there is usually no anatomic abnormality, the underlying cause is a disorder in the hypothalamus or the pituitary gland. African pygmies have a normal growth hormone level. However, the growth hormone disorder is present or the organ, especially the bone tissue, which is affected by the hormone, fails to respond to the hormone. Pituitary dwarfism is generally noticed in the first year of life. While the child develops, his/her face remains undeveloped and babyish and his/her body remains pudgy. The bones are proportionally small, and the intelligence level may be normal or even above the average. Pituitary dwarfism is treated by administering to the patient the growth hormone obtained from a pituitary gland in the operation or autopsy. Today the growth hormone is synthesized and commercially available. When these drugs are used, the patients reach a growth rate that is 7,5 cm more per year as compared to the growth rate before the treatment. Other types of dwarfism do not respond to the hormone treatment. Congenital dwarfism: The dwarfism is congenital in the mongolism, which is characterized by mental deficiency, abnormal facial appearance and some abnormalities in the hands and the feet. The dwarfism observed in the case of achondroplasia is characterized by short arms and legs, normal body and normal intelligence level. In the case of gargoylism, the dwarfism exists together with mental deficiency, profound deformities in the skeleton and the skull and the skin damage. Cretinism, which is the congenital deficiency in the function of the thyroid gland, involves mental deficiency along with dwarfism. Dwarfism is also present in Turner syndrome characterized by the missing or incomplete chromosome. Currently, the growth hormone therapy, when applied alone, has failed to treat the dwarfism in 70% of the patients. The reason for this is that it is not possible to provide the effect of synthesis of a sufficient level of growth factor by the growth hormone when interacting with the liver. As a result, the presence of the need for a composition for treating growth/development/dwarfism syndromes and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art.
Object of the Invention
In order to eliminate the disadvantages of the state of the art, an object of the invention is to trigger the production of the growth hormone. Another object of the invention is to increase the expression of the growth factor-2 in a tissue selective manner and trigger the upright growth in the bones. Another object of the invention is to elevate the levels of deiodinase D2 and D1. Another object of the invention is to provide the fat burning by increasing the expression of malic enzyme. Another object of the invention is to accelerate the conversion of T4 hormone to t3. Another object of the invention is to provide an increase in the expression of igf-1 mRNA in the bone tissue. Another object of the invention is to provide an increase in the expression of tgf-1 mRNA in the bone tissue. Another object of the invention is to support the release of the growth hormone and the production of igf-1. Another object of the invention is to support the release of the thyroid hormone. Another object of the invention is to trigger the upright growth in the bones. In order to achieve the aforesaid advantages, the invention is a composition for treating growth/development/dwarfism syndromes, said composition being obtained by the components selected from the group comprising dimethyldioscin, methyldioscin, 3,7-beta-diosgenin and 7-oxo-diosgenin that are used individually or in combinations. The structural and characteristic features and all the advantages of the invention will become more clearly understood from the detailed description provided below and therefore, the evaluation must be made taking this detailed description into consideration.
Technical Field
The invention relates to a somatotropic and pro-thyrogenic composition formed for treating growth/development/dwarfism syndromes.
State of the Art
Dwarfism is a condition of an individual who is smaller than the normal and who lacks the ability of normal development. Dwarfism occurs in the animals and also in the plants. It is not possible to make a certain classification as to what height would cause a human to be called a dwarf. The height that leads an adult human to be considered as a dwarf generally varies between one and one and a half meter. Normal persons may have dwarf children and the dwarf persons may have normal children. The causes of dwarfism in the human may be examined in two groups, namely the congenital dwarfism and the dwarfism that occurs later in life due to some diseases. Dwarfism resulting from disease: The dwarfism may result from chronic kidney disease, cystic fibrosis and celiac disease where the nutrient absorption is impaired, the heart and lung diseases where there is low oxygen level in the blood, and the malnutrition during the early years of life. The treatment of these diseases generally provides a treatment for the dwarfism also. The treatable type of dwarfism known as the pituitary dwarfism is the type in which the medicine has the biggest interest. This generally results from the inability of the pituitary gland to secrete sufficient growth hormone. Although there is usually no anatomic abnormality, the underlying cause is a disorder in the hypothalamus or the pituitary gland. African pygmies have a normal growth hormone level. However, the growth hormone disorder is present or the organ, especially the bone tissue, which is affected by the hormone, fails to respond to the hormone. Pituitary dwarfism is generally noticed in the first year of life. While the child develops, his/her face remains undeveloped and babyish and his/her body remains pudgy. The bones are proportionally small, and the intelligence level may be normal or even above the average. Pituitary dwarfism is treated by administering to the patient the growth hormone obtained from a pituitary gland in the operation or autopsy. Today the growth hormone is synthesized and commercially available. When these drugs are used, the patients reach a growth rate that is 7,5 cm more per year as compared to the growth rate before the treatment. Other types of dwarfism do not respond to the hormone treatment. Congenital dwarfism: The dwarfism is congenital in the mongolism, which is characterized by mental deficiency, abnormal facial appearance and some abnormalities in the hands and the feet. The dwarfism observed in the case of achondroplasia is characterized by short arms and legs, normal body and normal intelligence level. In the case of gargoylism, the dwarfism exists together with mental deficiency, profound deformities in the skeleton and the skull and the skin damage. Cretinism, which is the congenital deficiency in the function of the thyroid gland, involves mental deficiency along with dwarfism. Dwarfism is also present in Turner syndrome characterized by the missing or incomplete chromosome. Currently, the growth hormone therapy, when applied alone, has failed to treat the dwarfism in 70% of the patients. The reason for this is that it is not possible to provide the effect of synthesis of a sufficient level of growth factor by the growth hormone when interacting with the liver. As a result, the presence of the need for a composition for treating growth/development/dwarfism syndromes and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art.
Object of the Invention
In order to eliminate the disadvantages of the state of the art, an object of the invention is to trigger the production of the growth hormone. Another object of the invention is to increase the expression of the growth factor-2 in a tissue selective manner and trigger the upright growth in the bones. Another object of the invention is to elevate the levels of deiodinase D2 and D1. Another object of the invention is to provide the fat burning by increasing the expression of malic enzyme. Another object of the invention is to accelerate the conversion of T4 hormone to t3. Another object of the invention is to provide an increase in the expression of igf-1 mRNA in the bone tissue. Another object of the invention is to provide an increase in the expression of tgf-1 mRNA in the bone tissue. Another object of the invention is to support the release of the growth hormone and the production of igf-1. Another object of the invention is to support the release of the thyroid hormone. Another object of the invention is to trigger the upright growth in the bones. In order to achieve the aforesaid advantages, the invention is a composition for treating growth/development/dwarfism syndromes, said composition being obtained by the components selected from the group comprising dimethyldioscin, methyldioscin, 3,7-beta-diosgenin and 7-oxo-diosgenin that are used individually or in combinations. The structural and characteristic features and all the advantages of the invention will become more clearly understood from the detailed description provided below and therefore, the evaluation must be made taking this detailed description into consideration.
Related Publications
This study is un-published. See below for other available versions.
Published Versions
Report a Problem
Found a serious problem with the data, such as disclosure risk or copyrighted content? Let us know.
This material is distributed exactly as it arrived from the data depositor. ICPSR has not checked or processed this material. Users should consult the investigator(s) if further information is desired.